AZ876

CAS No. 898800-26-5

AZ876( —— )

Catalog No. M19966 CAS No. 898800-26-5

AZ876 is a potent highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 78 In Stock
10MG 120 In Stock
25MG 157 In Stock
50MG 193 In Stock
100MG 343 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AZ876
  • Note
    Research use only, not for human use.
  • Brief Description
    AZ876 is a potent highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively.
  • Description
    AZ876 is a potent highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    LXR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    898800-26-5
  • Formula Weight
    439.57
  • Molecular Formula
    C24H29N3O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 2.5 mg/mL
  • SMILES
    CC(C)(C)N1C(=O)C(Nc2ccc(cc2)N2CCCCC2)=C(c2ccccc2)S1(=O)=O
  • Chemical Name
    2-(11-Dimethylethyl)-5-phenyl-4-[[4-(1-piperidinyl)phenyl]amino]-3(2H)-isothiazolone 11-dioxide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.van der Hoorn J et al. Low dose of the liver X receptor agonist AZ876 reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol. 2011 Apr;162(7):1553-63.
molnova catalog
related products
  • Cistantubuloside C1

    Cistantubuloside C1 is a natural product for research related to life sciences.

  • Dehydroepiandrostero...

    Prasterone sulfate is a HSD11B1 expression inhibitor.

  • CALP2

    Cell-permeable calmodulin (CaM) antagonist that binds to the EF-hand/Ca2+-binding site. CALP2 has been demonstrated to inhibit CaM-dependant phosphodiesterase activity and increase intracellular Ca2+ concentrations by modulating Ca2+-channel activity. CALP2 has also been shown to be a potent activator of alveolar macrophages.